A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
PHASE3
This randomized, double-blind, parallel group study compares the efficacy a...
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
PHASE3
The purpose of this study is to evaluate the efficacy and safety of deucrav...
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
PHASE3
The purpose of this study is to verify the superiority of ASP015K in combin...
Adherence Rate to DMARDS in Egyptian Patients With RA
N/A
The study aims at determining adherence rate to DMARDS and predicting facto...
Status
Unknown
Location
Multiple Locations
Start Date
2019-11
Trial ID
NCT03316027
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
N/A
The current study will assess the real - life effectiveness of adalimumab i...
Status
Completed
Location
Rheumatology Clinic /ID# 54768
Start Date
2011-06-29
Trial ID
NCT01387802
A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs
N/A
The purpose of this Italian multicenter study is to collect prospective cli...
Status
Completed
Location
ASST Spedali Civili Brescia
Start Date
2017-06-09
Trial ID
NCT03131661
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
PHASE3
This study is designed to compare the effectiveness of the experimental dru...
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
PHASE3
This open-label study will evaluate the efficacy and safety of tocilizumab ...